Catalyst Tracker

02/21/2024 04:46 PM ET

Regeneron Pharmaceuticals REGN date announcement

Regeneron Pharmaceuticals now has 20 catalyst announcements on the calendar after revealing the date on which they will release trial results for Linvoseltamab (REGN5458) - (LINKER-MM1). On March 31, 2024, Regeneron Pharmaceuticals will announce top-line [...]

Read More
02/21/2024 04:46 PM ET

Ionis Pharmaceuticals IONS earnings announcement

Ionis Pharmaceuticals revealed their most recent quarterly earnings data, in which both revenue and EPS ended up higher than estimates. Revenue was reported to be $325M and EPS was -$0.06. Ionis Pharmaceuticals' EPS is [...]

Read More
02/21/2024 04:46 PM ET

PHAXIAM Therapeutics S.A. THTX earnings announcement

Theratechnologies beat their EPS estimate and fell in line with their revenue estimate, according to their recent quarterly earnings data. Revenue was $23.45M, exceeding estimates by 0.39%. For revenue, that is [...]

Read More
02/21/2024 04:46 PM ET

Ventyx Biosciences UTHR earnings announcement

United Therapeutics Corporation exceeded their revenue estimate and fell in line with their EPS estimate, according to their recent quarterly earnings data. The revenue estimate was $575.87M, but the actual figure was [...]

Read More
02/21/2024 04:46 PM ET

Calliditas Therapeutics AB CALT earnings announcement

Calliditas Therapeutics AB revealed their most recent quarterly earnings data, in which both revenue and EPS ended up higher than estimates. Revenue, at $42.41M, was the biggest surprise for the quarter, as it [...]

Read More
02/21/2024 04:46 PM ET

AbCellera Biologics ABCL earnings announcement

AbCellera Biologics fell in line with their revenue estimate but fell short of their EPS estimate, according to their recent quarterly earnings data. EPS was -$0.16, missing estimates by 23.1%. AbCellera [...]

Read More
02/21/2024 04:46 PM ET

Halozyme Therapeutics HALO earnings announcement

Halozyme Therapeutics revealed their most recent quarterly earnings data for Q4. Revenue was reported to be $230.04M and EPS was $0.82. Halozyme Therapeutics' revenue is now up $48.54M (+26.7%) over the past year.

The market [...]

Read More
02/20/2024 04:45 PM ET

Palatin Technologies PTN date announcement

After specifying an announcement date for PL8177-205 trial results, Palatin Technologies now has seven catalyst announcements planned. Palatin Technologies has an announcement scheduled for March 31, 2024 regarding their recent Phase 2 trial. The community [...]

Read More
02/20/2024 04:45 PM ET

Monopar Therapeutics ARVN results announcement

Arvinas gave investors an update to their Phase 1 trial for ARV-102. The results were summarized as follows:

"Phase 1 dosing commenced, noted February 20, 2024."

This is one of three upcoming announcements for the [...]

Read More
02/20/2024 04:45 PM ET

Freeline Therapeutics Holdings plc NRXP date announcement

NRX Pharmaceuticals now has four catalyst announcements on the calendar after revealing the date on which they will release trial results for HTX-100 (NRX-100) (Ketamine Hydrochloride). On December 31, 2024, NRX Pharmaceuticals will announce top-line [...]

Read More
02/20/2024 04:45 PM ET

Disc Medicine IRON date announcement

Disc Medicine already had two catalyst announcements coming up, but they added another one today. Now that the Phase 1/2 trial of DISC-0974 is completed, Disc Medicine will announce their top-line results on December 31, [...]

Read More
02/20/2024 04:45 PM ET

Immuneering Corporation IMRX date announcement

On April 30, 2024, Immuneering Corporation will announce top-line results for their recent Phase 1/2 trial for IMM-1-104. Our calculations give the drug a 60.9% chance of moving on to the next stage.

Whether it [...]

Read More